Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
POLICY PAPERS
November 03, 2022
Few labor-based pathways for regular migration are available for people in Northern Central America. This paper summarizes the state of labor-based migration channels in the region and argues that extending those channels is a necessary complement to asylum reform. It offers five recommendations for...
POLICY PAPERS
October 31, 2022
The US is looking for ways to stimulate economic development within, and expand legal migration pathways from, El Salvador, Guatemala, and Honduras. At the same time, US employers are struggling with shortages in key industries. A Global Skill Partnership between the US and El Salvador, Guatemala, o...
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.
POLICY PAPERS
October 04, 2022
In this paper, we report the results of a horizon-scanning exercise to source opportunities for global health R&D investment—that is, high-value potential biomedical innovations which are currently underfunded but which could be transformative for health, quality of life, and health security in LMIC...
Blog Post
September 29, 2022
With a little more than two years left in the current administration’s term, now is the time to lay the foundation for a robust infrastructure so that US leadership translates into helping more refugees in the decades to come. If properly resourced and supported, the Resettlement Diplomacy Network c...
Blog Post
September 21, 2022
While any global leader needs to “walk and chew gum” at the same time, the effort to rapidly welcome Afghans required intense engagement from the highest levels of government to service providers on the frontlines. This major undertaking took place in the wake of an administration that targeted the ...
Blog Post
June 28, 2022
CGD has set up a working group to examine different ways to purchase antimicrobials in LMICs in order to identify actionable policies to improve access and stewardship for key products and increase funding for research into new ones. We are launching today the Working Group’s first working paper.